Immune to Cancer: The CRI Blog
-
Checkpoint Immunotherapy Combination Approved for First-line Treatment of Advanced Kidney Cancer
The combination of checkpoint immunotherapies against PD-1 and CTLA-4 significantly improved survival and response rates compared to…
-
AACR18 Day 2 Update: What’s Next for Cancer Immunotherapy?
CRI scientists kicked off the opening plenary session at AACR18 and discussed several promising avenues of immunotherapy…
-
AACR18: Driving Innovative Cancer Science to Patient Care
This year’s annual AACR meeting boasts an impressive lineup of presentations highlighting both clinical and preclinical immunotherapy…
-
Healthcare Experts Tackle Tough Challenges at Fortune Brainstorm HEALTH 2018
CRI CEO highlights next steps in immunotherapy’s advancement at Fortune’s premier healthcare conference
-
Running for Hope at the 2018 UA New York City Half Marathon
Eighteen members of Team CRI ran the 13.1 mile 2018 United Airlines New York City Half Marathon…
-
Homesick Shows the Small Moments in Life with Cancer and Fundraises for Lifesaving Research
Behind-the-scenes of a new based-on-a-true-story comedy web series, “Homesick,” about an American living in London with a…
-
Durvalumab Becomes First Immunotherapy Approved for Stage III Lung Cancer
Immunotherapy tripled the median progression-free survival rate among lung cancer patients compared to those who received only…
-
Recap of the Fourth Annual Immuno-Oncology 360° Conference
The Fourth Annual Immuno-Oncology 360° Conference focused on comprehensive strategies for advancing immunotherapy, and was held from February…
-
Partner Spotlight: Thomas Hudson, Abbvie
We introduce you to Thomas Hudson, MD, vice president, head of oncology discovery and early development at…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.